 | |
| Clinical data | |
|---|---|
| Other names | Raxatrigine; CNV1014802; GSK-1014802; BIIB 074 |
| Routes of administration | By mouth |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H19FN2O2 |
| Molar mass | 314.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vixotrigine (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name), formerly known asraxatrigine (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name), is ananalgesic which is under development by Convergence Pharmaceuticals for the treatment oflumbosacral radiculopathy (sciatica) andtrigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be aselectivecentralNav1.3blocker, but was subsequently redefined as a selectiveperipheralNav1.7 blocker.[citation needed] Following this, vixotrigine was redefined once again, as a non-selectivevoltage-gated sodium channel blocker.[citation needed] As of January 2018, it is inphase IIIclinical trials for trigeminal neuralgia and is inphase II clinical studies forerythromelalgia andneuropathic pain.[4] It was previously under investigation for the treatment ofbipolar disorder, but development for this indication was discontinued.[4]
